Biovie Inc (BIVI) — Supplier relationships and operational posture investors need to know

BioVie Inc. operates as a clinical-stage biotechnology company that acquires and advances novel therapeutic assets and commercializes them through clinical development, licensing and public market capital raises; the company monetizes by developing drug candidates for neurodegenerative and inflammatory indications and capturing value via licensing, commercialization or asset sales following clinical validation. Revenue generation is still development-stage and capital markets activity is an active part of the company’s funding and investor relations strategy. For a concise vendor and counterparty view, continue reading or visit the Null Exposure home page to see coverage across similar suppliers: https://nullexposure.com/

Key operating signals and what they imply for supplier risk

• Outsourced manufacturing and clinical execution. BioVie reports no owned manufacturing and relies on Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to execute trials and produce drug candidates, implying outsized operational dependence on specialized external vendors.
• Mixed lease posture with both short- and long-term commitments. The company maintains a five‑year San Diego lease (60 months) with annual escalators and a smaller annual HQ rent renewed yearly; this combination suggests moderate fixed overhead but also some flexibility at headquarters.
• Concentrated spend bands consistent with smaller biotechs. Contractual obligations and royalty caps point to vendor spend typically in the sub-$1M range per counterparty, with some obligations in the $100k–$1M band.
• Low institutional ownership and thin market capitalization. These capital structure facts increase the strategic importance of PR, investor relations and bank/advisor relationships to maintain funding momentum.

If you want a structured supplier scorecard for BIVI and peer comparatives, see our platform at https://nullexposure.com/ — tailored reports are available.

What BIVI’s counterparties look like (annotated list) Below I cover every named counterparty extracted from public disclosures and press coverage, with a plain-English summary and a concise source note for each relationship.

RedChip Companies / RedChip Companies, Inc. — investor communications partner

BioVie has engaged RedChip to host investor webinars and broadcast interviews, positioning RedChip as a recurring investor relations and PR host for investor-facing events throughout FY2025–FY2026. According to press releases and syndicated local wire items, RedChip hosted BioVie presentations and interviews that the company used to communicate data and corporate updates (see multiple press releases, Dec 2025 and early 2026): https://www.globenewswire.com/ and related local wires.

The Nasdaq Capital Market / Nasdaq — listing and market infrastructure

BioVie’s Class A common stock was approved for listing on the Nasdaq Capital Market under the symbol BIVI following a public offering, and Nasdaq also lists related warrants (BIVIW). A GlobeNewswire filing (2020) and subsequent SEC-related coverage note the listing and later warrant trading (2025). Source: GlobeNewswire (2020) and related SEC/market notices (2025): https://www.globenewswire.com/ and https://www.stocktitan.net/sec-filings/BIVI/page-3.html

Kingswood Capital Markets — book-running manager on public offering

Kingswood Capital Markets served as one of the joint book-running managers on BioVie’s public offering, indicating an investment banking role in BioVie’s equity capital formation. This is recorded in the offering release (2020). Source: GlobeNewswire press release (2020): https://www.globenewswire.com/

ThinkEquity / ThinkEquity LLC — underwriter and over-allotment participant

ThinkEquity acted as joint book-running manager in BioVie’s offering and ThinkEquity LLC later exercised over‑allotment and received underwriter warrants, demonstrating active underwriter participation in capital markets transactions. The offering release and subsequent SEC filing excerpts document the underwriter’s allotment and warrants (2020; filings 2025/2026). Source: GlobeNewswire (2020) and related stock filing excerpts: https://www.globenewswire.com/ and https://www.stocktitan.net/sec-filings/BIVI/page-3.html

Moelis & Co. — financial advisor on acquisition

Moelis & Co. acted as exclusive financial advisor to BioVie on its acquisition of NeurMedix assets, reflecting use of boutique investment bank expertise for M&A and transaction structuring. This engagement appears in the acquisition announcement (2021). Source: GlobeNewswire (2021): https://www.globenewswire.com/

Hogan Lovells — legal counsel

Hogan Lovells served as legal counsel to BioVie in the NeurMedix asset acquisition, indicating reliance on large law-firm counsel for transactional and regulatory work. The legal counsel assignment is disclosed in the 2021 acquisition release. Source: GlobeNewswire (2021): https://www.globenewswire.com/

The Weinstein Group — scientific diligence advisor

The Weinstein Group advised BioVie on scientific diligence for the NeurMedix assets and trial planning, signaling the use of outside scientific advisors to vet acquisition targets and development plans. Source: GlobeNewswire (2021): https://www.globenewswire.com/

NeurMedix, Inc. — acquired asset counterparty

BioVie announced the acquisition of biopharma assets from privately-held NeurMedix in 2021, a strategic asset purchase that expanded BioVie’s clinical pipeline. Details are in BioVie’s acquisition announcement (2021). Source: GlobeNewswire (2021): https://www.globenewswire.com/

LifeSci Advisors, LLC — investor relations contact

BioVie lists LifeSci Advisors as an investor relations contact in investor announcements, indicating a retained IR advisor for outreach to institutional and retail investors. This contact appears in press items announcing conference presentations and abstracts (2026). Source: StockTitan press items (2026): https://www.stocktitan.net/news/BIVI/bio-vie-announces-abstracts-accepted-for-presentation-at-the-2026-6m1sjtwourtj.html

Elixir Health Public Relations — media relations partner

Elixir Health PR is named as the media contact on press releases, confirming a retained public relations firm for media outreach and messaging. This contact detail appears in company press materials (2026). Source: StockTitan press items (2026): https://www.stocktitan.net/news/BIVI/bio-vie-announces-abstracts-accepted-for-presentation-at-the-2026-6m1sjtwourtj.html

West Coast Stock Transfer, Inc. — transfer agent / exchange agent role

West Coast Stock Transfer is identified as exchange agent in related filings, indicating the transfer agent role for shareholder exchanges and transactional logistics. This is recorded in transaction-related filings (2025/2026). Source: StockTitan SEC filing excerpts (2026): https://www.stocktitan.net/sec-filings/BIVI/page-3.html

Operational risk implications and investor takeaways BioVie’s supply-side and service relationships show a classic small-cap biotech operating model: acquisition-led pipeline build, reliance on banks, law firms and specialist advisors for transactions, and heavy dependence on outsourced CMOs and CROs for core development activities. The company’s fixed-cost profile is modest but includes a multi-year San Diego lease that creates a predictable near-term occupancy expense; other HQ rent is annual and low. Director consulting payments and modest royalty caps are consistent with a company managing close contractor relationships and tightly controlled cash outflows.

• Concentration and criticality: Manufacturing and clinical execution are critical and outsourced—vendor performance directly affects timelines and value crystallization.
• Maturity and contracting posture: The vendor mix (investment banks, law firms, PR/IR firms, transfer agent) is typical for a clinical-stage biotech transitioning from acquisition to trial-stage execution; contracts are a mix of long-term office lease and numerous professional services that are likely short to medium term.
• Spend profile: Public disclosures indicate most counterparty spend falls in sub-$1M bands per contract with isolated obligations capped at low six figures, which limits single-counterparty exposure but keeps the company sensitive to capital market access.

If you want granular supplier risk scoring for BIVI and comparable profile analysis for other small-cap biotech suppliers, explore our resource hub at https://nullexposure.com/.

Final perspective and action items BioVie’s strategic playbook centers on asset acquisition and outsourced development with a lightweight fixed-cost base and active use of market-facing advisors. For investors and operator-sourcing teams, the highest-priority checks are vendor validation for CMOs/CROs, confirmation of intellectual property and royalty structures, and sustained investor relations cadence to secure future funding rounds. For deeper vendor mapping and to commission tailored supplier diligence on BIVI or peers, visit https://nullexposure.com/ and request a supplier intelligence briefing.